|
1
|
Akram M, Iqbal M, Daniyal M and Khan AU:
Awareness and current knowledge of breast cancer. Biol Res.
50:332017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zaidi Z and Dib HA: The worldwide female
breast cancer incidence and survival, 2018. Cancer Res. Jul
1–2019.(Epub ahead of print). doi:
10.1158/1538-7445.AM2019-4191.
|
|
3
|
Ellis LM and Hicklin DJ: Resistance to
targeted therapies: Refining anticancer therapy in the era of
molecular oncology. Clin Cancer Res. 15:7471–7478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Network CGA; Cancer Genome Atlas Network,
: Comprehensive molecular portraits of human breast tumours.
Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Daniyal A, Santoso I, Gunawan NHP,
Barliana MI and Abdulah R: Genetic Influences in Breast Cancer Drug
Resistance. Breast Cancer (Dove Med Press). 13:59–85.
2021.PubMed/NCBI
|
|
6
|
Ji X, Lu Y, Tian H, Meng X, Wei M and Cho
WC: Chemoresistance mechanisms of breast cancer and their
countermeasures. Biomed Pharmacother. 114:1088002019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu W, Tan C, He Y, Zhang G, Xu Y and Tang
J: Functional miRNAs in breast cancer drug resistance. OncoTargets
Ther. 11:1529–1541. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Khordadmehr M, Shahbazi R, Ezzati H,
Jigari-Asl F, Sadreddini S and Baradaran B: Key microRNAs in the
biology of breast cancer; emerging evidence in the last decade. J
Cell Physiol. 234:8316–8326. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hanna J, Hossain GS and Kocerha J: The
potential for microRNA therapeutics and clinical research. Front
Genet. 10:4782019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Si W, Shen J, Zheng H and Fan W: The role
and mechanisms of action of microRNAs in cancer drug resistance.
Clin Epigenetics. 11:252019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tormo E, Ballester S, Adam-Artigues A,
Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide
J, Rovira A, et al: The miRNA-449 family mediates doxorubicin
resistance in triple-negative breast cancer by regulating cell
cycle factors. Sci Rep. 9:53162019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu X, Liu R, Wang M, Kumar AK, Pan F, He
L, Hu Z and Guo Z: MicroRNA-140 impedes DNA repair by targeting
FEN1 and enhances chemotherapeutic response in breast cancer.
Oncogene. 39:234–247. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and
Shao ZM: MicroRNA-200a confers chemoresistance by antagonizing
TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 18:742018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mulrane L, McGee SF, Gallagher WM and
O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res.
73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Cao F, Li X, Miao H, e J, Xing J
and Fu CG: miR-320b suppresses cell proliferation by targeting
c-Myc in human colorectal cancer cells. BMC Cancer. 15:7482015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Tang X, He Q, Yang X, Ren X, Wen X,
Zhang J, Wang Y, Liu N and Ma J: Overexpression of mitochondria
mediator gene TRIAP1 by miR-320b loss is associated with
progression in nasopharyngeal carcinoma. PLoS Genet.
12:e10061832016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lv GY, Miao J and Zhang XL: Long noncoding
RNA XIST promotes osteosarcoma progression by targeting Ras-related
protein RAP2B via miR-320b. Oncol Res. 26:837–846. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu X, Wang Y, Zhong W, Cheng H and Tian Z:
RNA binding protein RNPC1 suppresses the stemness of human
endometrial cancer cells via stabilizing MST1/2 mRNA. Med Sci
Monit. 26:e9213892020.PubMed/NCBI
|
|
20
|
Cho SJ, Jung YS, Zhang J and Chen X: The
RNA-binding protein RNPC1 stabilizes the mRNA encoding the
RNA-binding protein HuR and cooperates with HuR to suppress cell
proliferation. J Biol Chem. 287:14535–14544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi L, Xia T-S, Wei X-L, Zhou W, Xue J,
Cheng L, Lou P, Li C, Wang Y, Wei JF, et al: Estrogen receptor (ER)
was regulated by RNPC1 stabilizing mRNA in ER positive breast
cancer. Oncotarget. 6:12264–12278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng L, Zhang Z, Zhang S, Guo Q, Zhang F,
Gao L, Ni H, Guo X, Xiang C and Xi T: RNA binding protein RNPC1
inhibits breast cancer cell metastasis via activating
STARD13-correlated ceRNA network. Mol Pharm. 15:2123–2132. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hernandez-Aya LF and Gonzalez-Angulo AM:
Adjuvant systemic therapies in breast cancer. Surg Clin North Am.
93:473–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ponnusamy L, Mahalingaiah PKS and Singh
KP: Treatment schedule and estrogen receptor-status influence
acquisition of doxorubicin resistance in breast cancer cells. Eur J
Pharm Sci. 104:424–433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xue J-Q, Xia T-S, Liang X-Q, Zhou W, Cheng
L, Shi L, Wang Y and Ding Q: RNA-binding protein RNPC1: Acting as a
tumor suppressor in breast cancer. BMC Cancer. 14:3222014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhong ZF, Yu HB, Wang CM, Qiang WA, Wang
SP, Zhang JM, Yu H, Cui L, Wu T, Li DQ, et al: Furanodiene induces
extrinsic and intrinsic apoptosis in doxorubicin-resistant MCF-7
breast cancer cells via NF-κB-independent mechanism. Front
Pharmacol. 8:6482017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao HL, Xia YZ, Zhang YL, Yang L and Kong
LY: Vielanin P enhances the cytotoxicity of doxorubicin via the
inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and
K562 DOX-resistant cell lines. Phytomedicine. 58:1528852019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li YS, Zhao DS, Liu XY, Liao YX, Jin HW,
Song GP and Cui ZN: Synthesis and biological evaluation of
2,5-disubstituted furan derivatives as P-glycoprotein inhibitors
for Doxorubicin resistance in MCF-7/ADR cell. Eur J Med Chem.
151:546–556. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Muss HB, White DR, Richards F II, Cooper
MR, Stuart JJ, Jackson DV, Rhyne L and Spurr CL: Adriamycin versus
methotrexate in five-drug combination chemotherapy for advanced
breast cancer: A randomized trial. Cancer. 42:2141–2148. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valero V, Jones SE, Von Hoff DD, Booser
DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW,
Erban JK, et al: A phase II study of docetaxel in patients with
paclitaxel-resistant metastatic breast cancer. J Clin Oncol.
16:3362–3368. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Riggins RB, Schrecengost RS, Guerrero MS
and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett.
256:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen X, Lu P, Wang DD, Yang SJ, Wu Y, Shen
H-Y, Zhong SL, Zhao JH and Tang JH: The role of miRNAs in drug
resistance and prognosis of breast cancer formalin-fixed
paraffin-embedded tissues. Gene. 595:221–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Majumder S and Jacob ST: Emerging role of
microRNAs in drug-resistant breast cancer. Gene Expr. 15:141–151.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du F, Yu L, Wu Y, Wang S, Yao J, Zheng X,
Xie S, Zhang S, Lu X, Liu Y, et al: miR-137 alleviates doxorubicin
resistance in breast cancer through inhibition of
epithelial-mesenchymal transition by targeting DUSP4. Cell Death
Dis. 10:9222019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu T, Guo J and Zhang X: MiR-202-5p/PTEN
mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt
signaling pathway. Cancer Biol Ther. 20:989–998. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang JF, Wen CJ, Zhao GZ, Dai Y, Li Y, Wu
LX and Zhou HH: Overexpression of ABCB4 contributes to acquired
doxorubicin resistance in breast cancer cells in vitro. Cancer
Chemother Pharmacol. 82:199–210. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang R, Qin Y, Zhu G, Li Y and Xue J: Low
serum miR-320b expression as a novel indicator of carotid
atherosclerosis. J Clin Neurosci. 33:252–258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lv QL, Du H, Liu YL, Huang YT, Wang GH,
Zhang X, Chen SH and Zhou HH: Low expression of microRNA-320b
correlates with tumorigenesis and unfavorable prognosis in glioma.
Oncol Rep. 38:959–966. 2017. View Article : Google Scholar : PubMed/NCBI
|
